Clinical analysis of adjuvant hyperthermic intravesical chemotherapy for treating non-muscle-invasive bladder cancer

Abstract

Objective To investigate the safety and effect of adjuvant hyperthermic intravesical chemotherapy for nonmuscle invasive bladder cancer. Methods From February 2011 to February 2016, 150 patients with primary or recurrent nonmuscle invasive bladder cancer who underwent transurethral resection of the bladder tumour (TURBT) were randomly assigned to the treatment group A, group B and group C. Group A was assigned to receive intravesical Bacillus Calmette-Gurin (BCG)for adjuvant treatment(50 cases), group B was assigned to receive intravesical chemotherapy of MMC combined with external thermal field thermotherapy (50 cases), and group C was assigned to receive intravesical chemotherapy of MMC alone (50 cases). Minimum follow-up time was 2 years.The safety evaluation end points included subjective and objective side effects and complications. Results Of the 150 randomly assigned patients, 145 completed the study and were analyzed statistically valid. In the group A, of the 48 patients , 6 recurred (12.5%). In the group 2, of the 48 patients, 5 recurred (10.4%). In the group C, of the 49 patients, 15 recurred (30.6%). According to the log-rank test, three methods were significant differences (P=0.006) . The recurrence-free rate in the two treatment groups (A and B) were significantly better than that of the treatment group C. Conclusions In our study, intravesical chemotherapy of MMC combined with hyperthermia is obviously more effective than that of intravesical chemotherapy of MMC alone. It is a good option for BCG therapy as adjuvant treatment for intermediate-and high-risk NMIBC. It is a good method for patient to tolerate, which is safe and feasible. Key words: Urinary Bladder Neoplasms; Mitomycin; Chemotherapy, Cancer, Regional Perfusion